AHMEDABAD:
Pharmaceutical and healthcare major
Zydus
Cadila and Taiwan’s specialty pharmaceutical company
TLC
on Wednesday announced that they have signed an agreement to market liposomal amphotericin B in India. That is a
critical drug
to treat mucormycosis or black fungus.
Under the terms of the agreement, TLC will manufacture and supply liposomal amphotericin B (AmphoTLC) on a non-exclusive basis to Zydus Cadila. The Ahmedabad-based pharmaceutical company will market this critical drug in India.
AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis. With the surge of infections in India, AmphoTLC will help to address the country’s acute liposomal amphotericin B shortage, Zydus said.
“With India facing an acute shortage of the drug to treat mucormycosis, we are making this critical drug available in India on an immediate basis,” said Sharvil Patel, managing director, Cadila Healthcare Ltd, the flagship company of
Zydus Cadila Group
.
The Central Drugs Standard Control Organization (CDSCO) of India has approved the new drug application (NDA) of TLC for amphotericin B liposome for immediate importation in line with usage and indication, Zydus said in its statement.
“We will be delivering the first batch of AmphoTLC to India to help assuage the urgent need for one of the safest and most effective antifungal drugs very soon,” said George Yeh, president, TLC.
Start a Conversation
Post comment